Alpha 1-Antitrypsin Deficiency Clinical Trial
Official title:
Randomized Double-Blind Comparison of an Alpha-1 Proteinase Inhibitor (Kamada API) With a Currently Marketed API Product in Individuals With Alpha-1 Antitrypsin Deficiency
The primary purpose of this Phase II/III study is to demonstrate that Kamada-API, a new API concentrate manufactured by Kamada Ltd., is comparable to a currently marketed API product.
Alpha-1 Antitrypsin Deficiency, also called Alpha-1-Proteinase Inhibitor (API) deficiency,
is a genetic disorder characterized by the production of an abnormal amount of AAT protein
and reduced circulating levels of this protein. Subjects with AAT deficiency are at
increased risk for developing chronic obstructive pulmonary disease (COPD). It is believed
that this is the result of the chronic activity of elastase released by cells continually
present in the lungs in low numbers.
This study is a randomized, double-blind comparison of Kamada API, an Alpha-1-Proteinase
Inhibitor with a currently marketed API product.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
| Recruiting |
NCT03285100 -
The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation
|
N/A | |
| Completed |
NCT03636347 -
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
|
Phase 2 | |
| Completed |
NCT00396006 -
Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)
|
Phase 4 | |
| Completed |
NCT04174118 -
Study of DCR-A1AT in Healthy Adult Volunteers
|
Phase 1 | |
| Completed |
NCT05579431 -
A Phase 1, First-in-human Study of VX-634
|
Phase 1 | |
| Recruiting |
NCT05856331 -
Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
|
Phase 2 | |
| Recruiting |
NCT00571272 -
Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
|
||
| Completed |
NCT02168686 -
Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04204252 -
Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD
|
Phase 3 | |
| Completed |
NCT00067756 -
4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?
|
Phase 2 | |
| Completed |
NCT00295061 -
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
|
Phase 3 | |
| Completed |
NCT00001462 -
Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals
|
N/A | |
| Active, not recruiting |
NCT05297812 -
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease
|
||
| Completed |
NCT03114020 -
Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency
|
Phase 2 | |
| Completed |
NCT00377416 -
Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency
|
Early Phase 1 | |
| Terminated |
NCT00005098 -
Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency
|
N/A | |
| Completed |
NCT03362242 -
Study of ARO-AAT in Normal Adult Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT05897424 -
Open Label Extension Study of INBRX-101 in Adults With AATD Emphysema
|
Phase 2 | |
| Completed |
NCT00301366 -
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
|
Phase 3 |